Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia
Luca Richeldi(Coral Reef Alliance), Ganesh Raghu(University of Washington), Sangeeta Bhorade(University of Chicago), Jonathan H. Chung(National Jewish Health), Mary Beth Scholand(University of Utah), David A. Lynch(McMaster University), Lars Hagmeyer(Krankenhaus Bethanien), Lisa Lancaster(Vanderbilt University Medical Center), David A. Sonetti(University of Wisconsin–Madison), Amy Hajari Case(The Ocean Cleanup), Nina Patel(Columbia University Irving Medical Center), Jeffrey L. Myers(University of Michigan), P. Sean Walsh(Veracyte (United States)), Steven D. Nathan(Inova Fairfax Hospital), Thomas V. Colby(Mayo Clinic in Arizona), Lori Lofaro(Veracyte (United States)), Murali Ramaswamy(University of Iowa), Steve D. Groshong(National Jewish Health), Shelley L. Schmidt(The Ocean Cleanup), Jing Huang(Veracyte (United States)), Fernando J. Martínez(University of Massachusetts Chan Medical School), John R. Davis(Saint Luke's Hospital), Giulia C. Kennedy(Veracyte (United States)), Karel Calero(University of South Florida), Daniel G. Pankratz(Veracyte (United States)), Jürgen Hetzel(University of Tübingen), Yoonha Choi(Ewha Womans University), Sadia Benzaquen(Jefferson Einstein Philadelphia Hospital), Umair Gauhar(University of Louisville), Gerard J. Criner(Temple University Hospital)
Cited by 82
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k